Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528197 | 1.00 | DPP4 (0.46) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL4574710 | 0.98 | DPP4 (0.44) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL3923326 | 0.98 | DPP4 (0.44) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL4042742 | 0.92 | LMNA (0.41) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL15232676 | 0.80 | DPP4 (0.50) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL19066301 | 0.79 | CA1 (0.43) | F2GBA1 | |
| SCHEMBL3430220 | 0.78 | DPP4 (0.48) | DPP4F2GBA1SRC | |
| SCHEMBL7987542 | 0.77 | CYP2C19 (0.42) | DPP4F2LMNAGBA1 | |
| SCHEMBL3619996 | 0.77 | — | — | |
| SCHEMBL3080670 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3212201-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI Pharma (FR) | 2017-09-06 | — | — | EP | disclosed |
| CN-105294688-B | 6-chlorine-N-(substituted benzyl)-1H-pyrrolo[2,3-b]pyridine-2-amide compound and preparation method as well as application thereof | 北京工业大学 | 2017-03-22 | — | — | CN | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2016066582-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2016-05-06 | — | — | WO | disclosed |
| CN-105294688-A | 6-chlorine-N-(substituted benzyl)-1H-pyrrolo[2,3-b]pyridine-2-amide compound and preparation method as well as application thereof | UNIV BEIJING TECHNOLOGY | 2016-02-03 | — | — | CN | disclosed |
| US-9139569-B2 | Fused tricyclic aryl compounds useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011092719-A2 | PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
| EP-1562902-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | DPP4 730/4885F2 19/4885ADRA2A 904/4885 |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | DPP4 240/4885F2 2893/4885ADRA2A 4324/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | DPP4 289/4885F2 2750/4885ADRA2A 4821/4885 |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, AADAC | DPP4 100/4885F2 3733/4885ADRA2A 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.